It was an application for Orphan Designation that was sent to the FDA by AMBS. The IND is the next step. If they get ODD, one of the incentives is waiving the IND fees, which are enormous, something like $2M if I am not mistaken. ODD is a big deal, especially if they get it for multiple indications - RP, CRVO, WS induced blindness. Plus, Glaucoma is not an ODD l, but a massive market. BP will be all over the opthamology franchise.